Penn Medicine Provider
Medical Oncology
Daniel Lefler, MD
he/him
5.0
(120)
Accepting new patients
Sees patients age 18 and up
Penn Hematology/Oncology Pennsylvania Hospital
View 1 additional location
Make an appointmentCall 800-789-7366

About me

  • Assistant Program Director, Hematology/Oncology Fellowship
  • Associate Clinical Director, Sarcoma Medical Oncology
  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: Cooper Medical School of Rowan University
  • Residency: Hospital of the University of Pennsylvania
  • Fellowship: Thomas Jefferson University Hospital

What my patients think about me

Average Rating
5.0

120 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
trust!
April 2025
4.0
4.0
given wrong info
April 2025
5.0
5.0
dr lefler was wonderful. he took the time to answer all of my questions and i never felt rushed. he was very kind. i'm so happy to have found him!
April 2025
4.0
4.0
i want more risk taking

Insurance accepted

My Locations

Learn about location
Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
Dr. Lefler is a Penn Medicine physician.

Qualifications and experience

My research

Lefler, D.S., Maki, R.G., Somaiah, N., …Basu Mallick, A. Characterizing the genomic landscape of perivascular epithelioid cell family of tumors in a real-world patient population using the Foundation Medicine genomic database , Connective Tissue Oncology Society Annual Meeting: 2024

Lefler, D.S., Moding, E.J., Basu Mallick, A mTOR activity: a biomarker for chemo- and immunotherapy response and outcomes in sarcomas , Connective Tissue Oncology Society Annual Meeting: 2024

Lefler, D.S., Elliott, A., Blomain, E.S., …Basu Mallick, A Characterizing patterns of mTORC1 activation across sarcomas using single-sample gene set enrichment analysis (ssGSEA) and a national biomarker database , ASCO Annual Meeting: 2024

Jirka GW, Lefler DS, Russo J, Bashir B. Colon adenocarcinoma and Birt-Hogg-Dubé syndrome in a young patient: case report and exploration of pathologic implications , Cancer Biol Ther: 2023

Lefler DS, Manobianco SA, Bashir B. Immunotherapy resistance in solid tumors: mechanisms and potential solutions , Cancer Biol Ther: 2023

Robbins J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, Ganetzky R, Lavu H, Giri VN, Miller J, Maley W, Shah AP, DiMeglio M, Ambelil M, Yu R, Sato T, Lefler DS Liver Transplantation in a Woman with Mahvash Disease , N Engl J Med: 2023

Lefler, D.S., Elliott, A., Maki, R.G., …Basu Mallick, A. Overexpression of cyclin dependent kinases and cyclins across sarcomas beyond CDK4 , Connective Tissue Oncology Society Annual Meeting: 2023

Daniel S Lefler, Marni Brisson Tierno, Babar Bashir. Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature. , Cancer Biol Ther, 23(1): 2022,112-116

Daniel S Lefler, Adam E Snook, Babar Bashir. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. , Immunotherapy , 14(11): 2022,885-902

Amy L Shaver, Swapnil Sharma, Nikita Nikita, Daniel S Lefler, Atrayee Basu-Mallick, Jennifer M Johnson, Meghan Butryn, Grace Lu-Yao. The Effects of Physical Activity on Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors: A Scoping Review , Cancers (Basel) , 13(24): 2021,6364